Bruno Balbi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4520850/publications.pdf

Version: 2024-02-01

94433 102487 4,720 128 37 66 h-index citations g-index papers 129 129 129 5670 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respiratory Research, 2005, 6, 71.	3.6	329
2	T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clinical and Experimental Immunology, 2009, 157, 316-324.	2.6	283
3	Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. European Respiratory Journal, 1998, 12, 380-386.	6.7	260
4	Tele-assistance in chronic respiratory failure patients: a randomised clinical trial. European Respiratory Journal, 2008, 33, 411-418.	6.7	220
5	Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived hospitalisation. European Respiratory Journal, 2020, 56, 2002096.	6.7	211
6	Bias toward use of a specific T cell receptor beta-chain variable region in a subgroup of individuals with sarcoidosis Journal of Clinical Investigation, 1988, 82, 1183-1191.	8.2	142
7	Increased MCP-1 and MIP- $1\hat{l}^2$ in bronchoalveolar lavage fluid of chronic bronchitics. European Respiratory Journal, 1999, 14, 160.	6.7	131
8	Comparison between exhaled and sputum oxidative stress biomarkers in chronic airway inflammation. European Respiratory Journal, 2004, 24, 1011-1017.	6.7	120
9	Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respiratory Research, 2014, 15, 77.	3.6	113
10	T-Lymphocytes with $\hat{I}^3\hat{I}' + \hat{V}^2$ Antigen Receptors Are Present in Increased Proportions in a Fraction of Patients with Tuberculosis or with Sarcoidosis. The American Review of Respiratory Disease, 1993, 148, 1685-1690.	2.9	101
11	Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD. Thorax, 2014, 69, 516-524.	5.6	99
12	Increased numbers of T lymphocytes with gamma delta-positive antigen receptors in a subgroup of individuals with pulmonary sarcoidosis Journal of Clinical Investigation, 1990, 85, 1353-1361.	8.2	95
13	MEKC of desmosine and isodesmosine in urine of chronic destructive lung disease patients. European Respiratory Journal, 2000, 15, 1039.	6.7	94
14	Hsp60 and Hsp10 down-regulation predicts bronchial epithelial carcinogenesis in smokers with chronic obstructive pulmonary disease. Cancer, 2006, 107, 2417-2424.	4.1	87
15	Tuberculous Pleural Effusions: Evidence for Selective Presence of PPD-Specific T-Lymphocytes at Site of Inflammation in the Early Phase of the Infection. The American Review of Respiratory Disease, 1987, 136, 575-579.	2.9	86
16	Seven-year time course of lung function, symptoms, health-related quality of life, and exercise tolerance in COPD patients undergoing pulmonary rehabilitation programs. Respiratory Medicine, 2007, 101, 1961-1970.	2.9	84
17	Prevalence and phenotype of subjects carrying rare variants in the Italian registry for alpha1-antitrypsin deficiency. Journal of Medical Genetics, 2005, 42, 282-287.	3.2	82
18	Bronchoalveolar lavage, sputum and exhaled clinically relevant inflammatory markers: values in healthy adults. European Respiratory Journal, 2007, 30, 769-781.	6.7	81

#	Article	IF	CITATIONS
19	Human Ciliated Bronchial Epithelial Cells: Expression of the HLA-DR Antigens and of the HLA-DR Alpha Gene, Modulation of the HLA-DR Antigens by Gamma-Interferon and Antigen-presenting Function in the Mixed Leukocyte Reaction. American Journal of Respiratory Cell and Molecular Biology, 1990, 3, 431-439.	2.9	80
20	Role of the Chemokine Receptors CXCR3 and CCR4 in Human Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 310-317.	5.6	79
21	Association of increased CCL5 and CXCL7 chemokine expression with neutrophil activation in severe stable COPD. Thorax, 2009, 64, 968-975.	5.6	79
22	T-Lymphocytes that Accumulate in the Lung in Sarcoidosis Have Evidence of Recent Stimulation of the T-Cell Antigen Receptor. The American Review of Respiratory Disease, 1992, 145, 1205-1211.	2.9	76
23	Decreased T lymphocyte infiltration in bronchial biopsies of subjects with severe chronic obstructive pulmonary disease. Clinical and Experimental Allergy, 2001, 31, 893-902.	2.9	73
24	Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression. European Respiratory Journal, 2017, 49, 1602006.	6.7	63
25	Efficacy of pulmonary rehabilitation in chronic respiratory failure (CRF) due to chronic obstructive pulmonary disease (COPD): The Maugeri Study. Respiratory Medicine, 2007, 101, 2447-2453.	2.9	60
26	Symptomatic Treatment of Recurrent Malignant Pleural Effusions with Intrapleurally AdministeredCorynebacterium parvum. The American Review of Respiratory Disease, 1987, 135, 885-890.	2.9	55
27	Convergent Sets of Data from In Vivo and In Vitro Methods Point to an Active Role of Hsp60 in Chronic Obstructive Pulmonary Disease Pathogenesis. PLoS ONE, 2011, 6, e28200.	2.5	55
28	Response to Treatment with an Analog of the Luteinizing-Hormone-Releasing Hormone in a Patient with Pulmonary Lymphangioleiomyomatosis. The American Review of Respiratory Disease, 1991, 143, 174-176.	2.9	54
29	A national program for detection of $\hat{l}\pm 1$ -antitrypsin deficiency in Italy. Respiratory Medicine, 1999, 93, 169-172.	2.9	53
30	Patients' characterization, hospital course and clinical outcomes in five Italian respiratory intensive care units. Intensive Care Medicine, 2010, 36, 137-142.	8.2	52
31	Inhaled Corticosteroids in Stable COPD Patients. Chest, 2000, 117, 1633-1637.	0.8	49
32	A pilot study of nurse-led, home monitoring for patients with chronic respiratory failure and with mechanical ventilation assistance. Journal of Telemedicine and Telecare, 2006, 12, 337-342.	2.7	49
33	Nerve ablation after bronchial thermoplasty and sustained improvement in severe asthma. BMC Pulmonary Medicine, 2018, 18, 29.	2.0	47
34	Health-related quality of life profiles, trajectories, persistent symptoms and pulmonary function one year after ICU discharge in invasively ventilated COVID-19 patients, a prospective follow-up study. Respiratory Medicine, 2021, 189, 106665.	2.9	46
35	Development of a Barthel Index based on dyspnea for patients with respiratory diseases. International Journal of COPD, 2016, $11,1199$.	2.3	44
36	TGF- \hat{l}^2 Signaling Pathways in Different Compartments of the Lower Airways of Patients With Stable COPD. Chest, 2018, 153, 851-862.	0.8	43

#	Article	IF	CITATIONS
37	Blood MCP-1 levels are increased in chronic obstructive pulmonary disease patients with prevalent emphysema. International Journal of COPD, 2018, Volume 13, 1691-1700.	2.3	43
38	Alveolar Macrophage Stimulation of T-Cell Proliferation in Autologous Mixed Lymphocyte Reactions. The American Review of Respiratory Disease, 1986, 133, 78-82.	2.9	42
39	Downmodulation of CXCL8/IL-8 receptors on neutrophils after recruitment in the airways. Journal of Allergy and Clinical Immunology, 2005, 115, 88-94.	2.9	37
40	General Characteristics and Risk Factors of Cardiovascular Disease among Interstate Bus Drivers. Scientific World Journal, The, 2012, 2012, 1-7.	2.1	35
41	Airway Clearance Techniques: The Right Choice for the Right Patient. Frontiers in Medicine, 2021, 8, 544826.	2.6	35
42	Acute Myelomonocytic Leukemia. Chest, 1985, 87, 259-260.	0.8	34
43	Primary human mesothelioma cells express class II MHC, ICAM-1 and B7–2 and can present recall antigens to autologous blood lymphocytes. , 1998, 78, 740-749.		33
44	Gait abnormalities of COPD are not directly related to respiratory function. Gait and Posture, 2017, 58, 352-357.	1.4	33
45	Oxidative stress, inflammation and disease activity biomarkers in lupus nephropathy. Lupus, 2020, 29, 311-323.	1.6	31
46	Lower Respiratory Tract Inflammation in Chronic Bronchitis. Chest, 1994, 106, 819-826.	0.8	30
47	Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease. Annals of Medicine, 2021, 53, 135-150.	3.8	30
48	Expression of vascular remodelling markers in relation to bradykinin receptors in asthma and COPD. Thorax, 2013, 68, 803-811.	5.6	29
49	Bacterial–viral load and the immune response in stable and exacerbated COPD: significance and therapeutic prospects. International Journal of COPD, 2016, 11, 445.	2.3	29
50	HSP60 activity on human bronchial epithelial cells. International Journal of Immunopathology and Pharmacology, 2017, 30, 333-340.	2.1	29
51	Helper T-lymphocytes in pulmonary sarcoidosis. Functional analysis of a lung T-cell subpopulation in patients with active disease. The American Review of Respiratory Disease, 1986, 133, 1086-90.	2.9	29
52	Incorporating telemedicine into the integrated care of the COPD patient a summary of an interdisciplinary workshop held in Stresa, Italy, 7–8 September 2017. Respiratory Medicine, 2018, 143, 91-102.	2.9	28
53	Preferential Usage of the T-Cell Antigen Receptor \hat{l}^2 -Chain Constant Region C \hat{l}^2 1 Element by Lung T-Lymphocytes of Patients with Pulmonary Sarcoidosis. The American Review of Respiratory Disease, 1991, 143, 635-639.	2.9	27
54	Efficacy of temporary positive expiratory pressure (TPEP) in patients with lung diseases and chronic mucus hypersecretion. The UNIKO < 0.000 sup > 0.000 project: a multicentre randomized controlled trial. Clinical Rehabilitation, 2013, 27, 336-346.	2.2	25

#	Article	IF	CITATIONS
55	Italian Registry of Patients with Alpha-1 Antitrypsin Deficiency: General Data and Quality of Life Evaluation. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 52-57.	1.6	23
56	Is dithiothreitol affecting cells and soluble mediators during sputum processing? A modified methodology to process sputum. Journal of Allergy and Clinical Immunology, 2002, 110, 667-669.	2.9	22
57	Smoking-related lung diseases: a clinical perspective. European Respiratory Journal, 2010, 35, 231-233.	6.7	22
58	High-Resolution Computed Tomography Quantitation of Emphysema Is Correlated with Selected Lung Function Values in Stable COPD. Respiration, 2012, 83, 383-390.	2.6	22
59	<p>Minimal Clinically Important Difference in Barthel Index Dyspnea in Patients with COPD</p> . International Journal of COPD, 2020, Volume 15, 2591-2599.	2.3	22
60	Physiological effects of meals in difficult-to-wean tracheostomised patients with chronic obstructive pulmonary disease. Intensive Care Medicine, 2005, 31, 236-242.	8.2	20
61	Maximal inspiratory and expiratory pressure measurement in tracheotomised patients. European Respiratory Journal, 2006, 27, 343-349.	6.7	20
62	Phospho-p38 MAPK Expression in COPD Patients and Asthmatics and in Challenged Bronchial Epithelium. Respiration, 2015, 89, 329-342.	2.6	20
63	Physiological responses to arm exercise in difficult to wean patients with chronic obstructive pulmonary disease. Intensive Care Medicine, 2006, 32, 1159-1166.	8.2	18
64	Management and outcomes of post-acute COVID-19 patients in Northern Italy. European Journal of Internal Medicine, 2020, 78, 159-160.	2.2	18
65	Population Genetic Screening for Alpha1-Antitrypsin Deficiency in a High-Prevalence Area. Respiration, 2011, 82, 418-425.	2.6	17
66	Weaning from Mechanical Ventilation Followed at Home with the Aid of a Telemedicine Program. Telemedicine Journal and E-Health, 2007, 13, 445-450.	2.8	15
67	Tracheostomy and related host–patogen interaction are associated with airway inflammation as characterized by tracheal aspirate analysis. Respiratory Medicine, 2009, 103, 201-208.	2.9	14
68	Hsp10 nuclear localization and changes in lung cells response to cigarette smoke suggest novel roles for this chaperonin. Open Biology, 2014, 4, 140125.	3.6	14
69	Exercise capacity and comorbidities in patients with obstructive sleep apnea. Journal of Clinical Sleep Medicine, 2020, 16, 531-538.	2.6	14
70	Lower respiratory tract infections in chronic obstructive pulmonary disease outpatients with tracheostomy and persistent colonization by P. aeruginosa. Respiratory Medicine, 2003, 97, 1205-1210.	2.9	12
71	Telemedicine and home care: controversies and opportunities. Breathe, 2006, 3, 148-158.	1.3	12
72	Efficacy of augmentation therapy for emphysema associated with \hat{l}_{\pm} sub>1-antitrypsin deficiency: enough is enough. European Respiratory Journal, 2016, 47, 35-38.	6.7	11

#	Article	IF	Citations
73	<p>Bacterial load and inflammatory response in sputum of alpha-1 antitrypsin deficiency patients with COPD</p> . International Journal of COPD, 2019, Volume 14, 1879-1893.	2.3	11
74	Suppression of the alveolitis in pulmonary sarcoidosis by oral corticosteroids. Lung, 1985, 163, 83-93.	3.3	10
75	COPD. Chest, 2003, 123, 983-986.	0.8	10
76	Health and social impacts of COPD and the problem of under-diagnosis. Multidisciplinary Respiratory Medicine, 2014, 9, 63.	1.5	10
77	Characteristics of COVID-19 Pneumonia Survivors With Resting Normoxemia and Exercise-Induced Desaturation. Respiratory Care, 2021, 66, 1657-1664.	1.6	10
78	Oxidative and Nitrosative Stress in the Pathogenesis of Obstructive Lung Diseases of Increasing Severity. Current Medicinal Chemistry, 2020, 27, 7149-7158.	2.4	10
79	MVarallo: A New MLike Alpha 1-Antitrypsin-Deficient Allele. Diagnostic Molecular Pathology, 2003, 12, 237-239.	2.1	8
80	Aging and Induced-Sputum Cells. Chest, 2005, 128, 4049-4050.	0.8	8
81	Comparing airways clearance techniques in chronic obstructive pulmonary disease and bronchiectasis: positive expiratory pressure or temporary positive expiratory pressure? A retrospective study. Brazilian Journal of Physical Therapy, 2017, 21, 15-23.	2.5	8
82	Something is changing in adherence to CPAP therapy: real world data after 1â€year of treatment in patients with obstructive sleep apnoea. European Respiratory Journal, 2020, 55, 1901419.	6.7	7
83	Different Expansions of T Lymphocyte Subpopulations in the Lung and Corticosteroid-induced Changes in Patients with Active Pulmonary Sarcoidosis. Annals of the New York Academy of Sciences, 1986, 465, 130-139.	3.8	6
84	Prevalence and clinical features of most frequent phenotypes in the Italian COPD population: the CLIMA Study. Multidisciplinary Respiratory Medicine, 2021, 16, 790.	1.5	6
85	A pilot study on the nonâ€invasive management of tracheobronchial secretions in tracheostomised patients. Clinical Respiratory Journal, 2019, 13, 637-642.	1.6	5
86	Muscarinic receptor M3 contributes to vascular and neural growth factor upâ€regulation in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 717-720.	5.7	5
87	Evaluation of Innate Immune Mediators Related to Respiratory Viruses in the Lung of Stable COPD Patients. Journal of Clinical Medicine, 2020, 9, 1807.	2.4	5
88	A young man with fever, dyspnoea and nonproductive cough. European Respiratory Journal, 1996, 9, 618-620.	6.7	4
89	Pulmonary rehabilitation in Italy: professional barriers to overcome. European Respiratory Journal, 2014, 44, 1382-1383.	6.7	4
90	General practitioners and rare lung diseases: a task force for the development of rare lung diseases educational material. Breathe, 2016, 12, 341-348.	1.3	4

#	Article	IF	Citations
91	The respiratory rehabilitation Maugeri network service reconfiguration after 1 year of COVID-19. Monaldi Archives for Chest Disease, $2021, 91, \ldots$	0.6	4
92	Requirement for Different Presenting Cells and for Different Processing Mechanisms by Human CD4 T Helper Clones Specific for M. tuberculosis Antigens. Human Immunology, 1998, 59, 265-274.	2.4	3
93	Implementation of a real-world based ICF set for the rehabilitation of respiratory diseases: a pilot study. Minerva Medica, 2020, 111, 239-244.	0.9	3
94	Popliteal Cysts in Chronic Hemodialysis Patients. Nephron, 1990, 56, 444-445.	1.8	2
95	Monitoring physical activity in cardiac and respiratory patients with the accelerometer fitbit alta HR®. , 2019, , .		2
96	Characteristics and clinical significance of the lymphocytic alveolitis in interstitial lung disorders. Lung, 1990, 168, 957-963.	3.3	1
97	Immunology and defence mechanisms. , 2013, , 39-44.		1
98	The fight against tobacco. Monaldi Archives for Chest Disease, 2013, 79, 5.	0.6	0
99	Roflumilast: the fourth Mousquetaire in COPD pharmacological treatment. Monaldi Archives for Chest Disease, 2013, 79, .	0.6	0
100	GPs Meet Rare Lung Disorders Task Force factsheet: Â-1 antitrypsin deficiency. Breathe, 2014, 10, 87-89.	1.3	0
101	A new deal for the Monaldi Archives for Chest Disease. Monaldi Archives for Chest Disease, 2017, 87, 837.	0.6	0
102	Integrated care of chronic degenerative non-communicable diseases and rehabilitation: the odd couple?. Monaldi Archives for Chest Disease, 2017, 87, 818.	0.6	0
103	Case finding of Alpha-1 antitrypsin deficiency: never wasted time!. Multidisciplinary Respiratory Medicine, 2018, 13, 3.	1.5	0
104	Accomplishments, engagements and new challenges for the Monaldi Archives for Chest Disease. Monaldi Archives for Chest Disease, 2019, 89, .	0.6	0
105	Extracorporeal Shock Waves Increase Markers of Cellular Proliferation in Bronchial Epithelium and in Primary Bronchial Fibroblasts of COPD Patients. Canadian Respiratory Journal, 2020, 2020, 1-14.	1.6	0
106	Immunology and defence mechanisms. , 2013, , 19-28.		0
107	Pro-and anti-fibrotic molecule balance in the bronchial mucosa of stable COPD patients. , 2015, , .		0
108	Tracheostomized (TCS) patients: Is it possible to manage noninvasively tracheobronchial secretions?. , 2015, , .		0

#	Article	IF	CITATIONS
109	Screening of alpha-1 antitrypsin deficiency in a blood donors cohort of the North-Italian area. , 2015, , .		0
110	The effect of bronchial thermoplasty on nerve C-fibers and inflammatory cells in patients with severe asthma. , $2015, \ldots$		0
111	Organization and content of pulmonary rehabilitation programs (PRP) in Italy: A national survey. , 2016, , .		0
112	Development of a Barthel index based on dyspnea for patients with respiratory diseases. , 2016, , .		0
113	TLR4 and NOD1 increase in stable COPD of increasing severity. Relationship with tissutal bacterial load. , 2016, , .		0
114	Selection of patients from Pulmonary Rehabilitation (PR) to Disease Management (DM) programmes. , 2017, , .		0
115	Late Breaking Abstract - Bacterial Load and Inflammation in Sputum from patients with Alpha-1-Antitrypsin Deficiency as compared with COPD Patients. , 2017, , .		0
116	Blood MCP-1 levels are increased in chronic obstructive pulmonary disease with prevalent emphysema. , $2018, , .$		0
117	What is the best frequency of exercise training in patients with moderate-to-severe COPD ?. , 2018, , .		0
118	Immunology and defence mechanisms. , 2019, , 20-27.		0
119	Patients with Alpha-1 antitrypsin Deficiency due to Null mutations have clinical peculiarities and should require personalized pulmonary management. , 2019, , .		0
120	Pulmonary rehabilitation after lung transplantation: Development of a protocol., 2019,,.		0
121	Extracorporeal shock waves increase markers of cellular proliferation in primary bronchial fibroblasts of COPD patients. , 2019, , .		0
122	Validation of a protocol for airway clearance in patients with ineffective cough. , 2019, , .		0
123	Effort tolerance and effectiveness of pulmonary rehabilitation in COPD patients with varying degrees of dyspnea during ADL., 2020,,.		0
124	Different clinical suspect that brings to the diagnosis of alpha1-antitrypsin deficiency. , 2020, , .		0
125	Minimal clinically important difference in Barthel dyspnoea after pulmonary rehabilitation in patients with Chronic Obstructive Pulmonary Disease. , 2020, , .		0
126	NoSAS: a possible screening questionnaire in patients with OSA and comorbidities. , 2020, , .		0

#	Article	IF	CITATIONS
127	Validation study of an innovative device to screen sleep respiratory disorders. , 2020, , .		O
128	In Memory of Claudio Ferdinando Donner. Respiration, 2022, 101, 106-107.	2.6	0